POLYNUCLEOTIDE ENCODING A NOVEL ACYL COENZYME A, MONOACYLGLYCEROL ACYLTRANSFERASE-3 (MGAT3), AND USES THEREOF
First Claim
1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
- (a) a polypeptide fragment of SEQ ID NO;
2 encoded by at least one of ATCC Deposit No;
PTA-4454 or PTA-4803;
(b) a polypeptide fragment of SEQ ID NO;
2 encoded by at least one of ATCC Deposit No;
PTA-4454 or PTA-4803, having MGAT activity;
(c) a polypeptide domain of SEQ ID NO;
2 encoded by at least one of ATCC Deposit No;
PTA-4454 or PTA-4803;
(d) a polypeptide epitope of SEQ ID NO;
2 or the encoded sequence encoded by at least one of ATCC Deposit No;
PTA-4454 or PTA-4803;
(e) a full length protein of SEQ ID NO;
2 encoded by at least one of ATCC Deposit No;
PTA-4454 or PTA-4803;
(f) a polypeptide comprising amino acids 2 to 341 of SEQ ID NO;
2, wherein said amino acids 2 to 341 comprises a polypeptide of SEQ ID NO;
2 minus the start methionine; and
(g) a polypeptide comprising amino acids 1 to 341 of SEQ ID NO;
2.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides novel polynucleotides encoding MGAT3 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel MGAT3 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, such as obesity. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
99 Citations
13 Claims
-
1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
-
(a) a polypeptide fragment of SEQ ID NO;
2 encoded by at least one of ATCC Deposit No;
PTA-4454 or PTA-4803;
(b) a polypeptide fragment of SEQ ID NO;
2 encoded by at least one of ATCC Deposit No;
PTA-4454 or PTA-4803, having MGAT activity;
(c) a polypeptide domain of SEQ ID NO;
2 encoded by at least one of ATCC Deposit No;
PTA-4454 or PTA-4803;
(d) a polypeptide epitope of SEQ ID NO;
2 or the encoded sequence encoded by at least one of ATCC Deposit No;
PTA-4454 or PTA-4803;
(e) a full length protein of SEQ ID NO;
2 encoded by at least one of ATCC Deposit No;
PTA-4454 or PTA-4803;
(f) a polypeptide comprising amino acids 2 to 341 of SEQ ID NO;
2, wherein said amino acids 2 to 341 comprises a polypeptide of SEQ ID NO;
2 minus the start methionine; and
(g) a polypeptide comprising amino acids 1 to 341 of SEQ ID NO;
2. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)
-
-
13. A method of treating Crohn'"'"'s disease comprising administering to a patient in need thereof an MGAT3 polypeptide or a modulator thereof.
Specification